JP2017503482A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503482A5 JP2017503482A5 JP2016536893A JP2016536893A JP2017503482A5 JP 2017503482 A5 JP2017503482 A5 JP 2017503482A5 JP 2016536893 A JP2016536893 A JP 2016536893A JP 2016536893 A JP2016536893 A JP 2016536893A JP 2017503482 A5 JP2017503482 A5 JP 2017503482A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cytomegalovirus
- nucleotide sequence
- antigenic fragment
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911135P | 2013-12-03 | 2013-12-03 | |
| US61/911,135 | 2013-12-03 | ||
| US201462055699P | 2014-09-26 | 2014-09-26 | |
| US62/055,699 | 2014-09-26 | ||
| PCT/EP2014/076466 WO2015082570A1 (en) | 2013-12-03 | 2014-12-03 | Cmv vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218641A Division JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503482A JP2017503482A (ja) | 2017-02-02 |
| JP2017503482A5 true JP2017503482A5 (OSRAM) | 2018-01-18 |
| JP6818551B2 JP6818551B2 (ja) | 2021-01-20 |
Family
ID=52232138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536893A Active JP6818551B2 (ja) | 2013-12-03 | 2014-12-03 | Ｃｍｖワクチン |
| JP2020218641A Active JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218641A Active JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10111945B2 (OSRAM) |
| EP (2) | EP3904522A1 (OSRAM) |
| JP (2) | JP6818551B2 (OSRAM) |
| CN (2) | CN105980570B (OSRAM) |
| AU (2) | AU2014359276B2 (OSRAM) |
| CA (1) | CA2932318C (OSRAM) |
| CY (1) | CY1124288T1 (OSRAM) |
| DK (1) | DK3077519T3 (OSRAM) |
| ES (1) | ES2868427T3 (OSRAM) |
| HR (1) | HRP20211015T1 (OSRAM) |
| HU (1) | HUE054579T2 (OSRAM) |
| LT (1) | LT3077519T (OSRAM) |
| PL (1) | PL3077519T3 (OSRAM) |
| PT (1) | PT3077519T (OSRAM) |
| RS (1) | RS61993B1 (OSRAM) |
| SI (1) | SI3077519T1 (OSRAM) |
| WO (1) | WO2015082570A1 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2604695T3 (da) | 2007-12-27 | 2023-01-16 | Univ Zuerich | Replikationsdefekte arenavirusvektorer |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| HUE054579T2 (hu) | 2013-12-03 | 2021-09-28 | Hookipa Biotech Gmbh | CMV vakcinák |
| ES2811093T3 (es) | 2014-11-13 | 2021-03-10 | Univ Geneve | Arenavirus trisegmentados como vectores de vacunas |
| EP3031822A1 (en) * | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| CN107921117B (zh) | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| SG11201803474UA (en) * | 2015-11-04 | 2018-05-30 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| JP7157662B2 (ja) * | 2015-11-12 | 2022-10-20 | ホオキパ バイオテック ジーエムビーエイチ | 癌ワクチンとしてのアレナウイルス粒子 |
| WO2017156146A1 (en) * | 2016-03-08 | 2017-09-14 | University Of Vermont And State Agricultural College | Modified arenavirus |
| WO2017180936A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| MA46584A (fr) * | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| WO2018083220A2 (en) | 2016-11-04 | 2018-05-11 | Hookipa Biotech Ag | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| US11613739B2 (en) | 2017-04-14 | 2023-03-28 | Regenxbio Inc. | Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells |
| WO2018204080A1 (en) * | 2017-05-02 | 2018-11-08 | The Scripps Research Institute | Compositions and methods related to arenavirus immunogens |
| WO2019216929A1 (en) * | 2018-05-11 | 2019-11-14 | City Of Hope | Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof |
| WO2020079586A1 (en) * | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| JP7179872B2 (ja) * | 2018-12-10 | 2022-11-29 | Ｋｍバイオロジクス株式会社 | サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン |
| US20220380805A1 (en) * | 2019-11-07 | 2022-12-01 | Universität Basel | Arenaviruses as vectors |
| AU2021287508B2 (en) * | 2020-06-09 | 2023-11-09 | Km Biologics Co., Ltd. | Fusion protein of pentamer and gB of cytomegalovirus, and vaccine containing said fusion protein |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| RU2756557C1 (ru) * | 2020-11-02 | 2021-10-01 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов |
| WO2022173605A2 (en) | 2021-02-10 | 2022-08-18 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| WO2024163912A2 (en) * | 2023-02-03 | 2024-08-08 | The Children's Medical Center Corporation | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
| WO2025056782A1 (en) | 2023-09-15 | 2025-03-20 | Hookipa Biotech Gmbh | Arenavirus formulations, methods and uses thereof |
| CN118221773B (zh) * | 2024-02-05 | 2025-09-09 | 首都医科大学附属北京儿童医院保定医院 | 与HLA相关的CMV pp65表位疫苗组合物与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| EP0436537A4 (en) * | 1988-01-29 | 1992-04-08 | Chiron Corporation | Recombinant cmv neutralizing proteins |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| JP2003527847A (ja) * | 2000-03-21 | 2003-09-24 | ジェンザイム・コーポレーション | 治療用抗サイトメガロウイルス化合物 |
| DE102004034461B4 (de) * | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| EP1856250B1 (en) * | 2005-02-15 | 2013-07-24 | The University of North Carolina At Chapel Hill | New live virus vaccines |
| WO2007109812A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| DK2604695T3 (da) | 2007-12-27 | 2023-01-16 | Univ Zuerich | Replikationsdefekte arenavirusvektorer |
| US8580276B2 (en) * | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| US20120093848A1 (en) * | 2009-06-26 | 2012-04-19 | Vectorite Biomedica Inc. | Immunogenic composition comprising peptides derived from cytomegalovirus and the use thereof |
| AU2011315447A1 (en) * | 2010-10-15 | 2013-05-09 | Glaxosmithkline Biologicals S.A. | Cytomegalovirus gB antigen |
| JP2014502848A (ja) | 2011-01-07 | 2014-02-06 | バイオサイエンス・スロバキア | ウイルス診断 |
| WO2012162428A1 (en) * | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| US11896636B2 (en) * | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| US8834307B2 (en) | 2011-10-06 | 2014-09-16 | Kawasaki Jukogyo Kabushiki Kaisha | Belt type continuously variable transmission |
| WO2013054199A2 (en) * | 2011-10-12 | 2013-04-18 | Novartis Ag | Cmv antigens and uses thereof |
| IN2014KN02929A (OSRAM) * | 2012-07-06 | 2015-05-08 | Novartis Ag | |
| WO2014140301A1 (en) | 2013-03-15 | 2014-09-18 | Université De Genève | Anti-mycobacterial vaccines |
| HUE054579T2 (hu) * | 2013-12-03 | 2021-09-28 | Hookipa Biotech Gmbh | CMV vakcinák |
| ES2811093T3 (es) | 2014-11-13 | 2021-03-10 | Univ Geneve | Arenavirus trisegmentados como vectores de vacunas |
| CN107921117B (zh) | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
| SG11201803474UA (en) | 2015-11-04 | 2018-05-30 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| JP7157662B2 (ja) | 2015-11-12 | 2022-10-20 | ホオキパ バイオテック ジーエムビーエイチ | 癌ワクチンとしてのアレナウイルス粒子 |
| IL262963B2 (en) | 2016-05-18 | 2025-01-01 | Hookipa Biotech Gmbh | Trisegmented PICHINDE viruses as vaccine vectors |
| WO2018083220A2 (en) | 2016-11-04 | 2018-05-11 | Hookipa Biotech Ag | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| AU2018247958A1 (en) | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| US20220380805A1 (en) | 2019-11-07 | 2022-12-01 | Universität Basel | Arenaviruses as vectors |
| US20230346906A1 (en) | 2020-05-29 | 2023-11-02 | Hookipa Biotech Gmbh | Cancer treatment strategies using arenavirus vectors |
-
2014
- 2014-12-03 HU HUE14820762A patent/HUE054579T2/hu unknown
- 2014-12-03 LT LTEP14820762.4T patent/LT3077519T/lt unknown
- 2014-12-03 HR HRP20211015TT patent/HRP20211015T1/hr unknown
- 2014-12-03 JP JP2016536893A patent/JP6818551B2/ja active Active
- 2014-12-03 AU AU2014359276A patent/AU2014359276B2/en active Active
- 2014-12-03 CN CN201480074709.4A patent/CN105980570B/zh active Active
- 2014-12-03 EP EP21165671.5A patent/EP3904522A1/en not_active Withdrawn
- 2014-12-03 DK DK14820762.4T patent/DK3077519T3/da active
- 2014-12-03 ES ES14820762T patent/ES2868427T3/es active Active
- 2014-12-03 EP EP14820762.4A patent/EP3077519B1/en active Active
- 2014-12-03 PT PT148207624T patent/PT3077519T/pt unknown
- 2014-12-03 PL PL14820762T patent/PL3077519T3/pl unknown
- 2014-12-03 SI SI201431830T patent/SI3077519T1/sl unknown
- 2014-12-03 WO PCT/EP2014/076466 patent/WO2015082570A1/en not_active Ceased
- 2014-12-03 CN CN202210602284.6A patent/CN115058452A/zh active Pending
- 2014-12-03 RS RS20210759A patent/RS61993B1/sr unknown
- 2014-12-03 US US15/101,363 patent/US10111945B2/en active Active
- 2014-12-03 CA CA2932318A patent/CA2932318C/en active Active
-
2018
- 2018-09-20 US US16/137,323 patent/US11554169B2/en active Active
-
2020
- 2020-12-28 JP JP2020218641A patent/JP7001807B2/ja active Active
-
2021
- 2021-04-26 AU AU2021202541A patent/AU2021202541A1/en not_active Abandoned
- 2021-06-29 CY CY20211100578T patent/CY1124288T1/el unknown
-
2022
- 2022-11-22 US US18/058,116 patent/US20230181725A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503482A5 (OSRAM) | ||
| HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
| Okamura et al. | Could live attenuated vaccines better control COVID-19? | |
| JP2021061848A5 (OSRAM) | ||
| JP2021182922A5 (OSRAM) | ||
| Begum et al. | Challenges and prospects of COVID‐19 vaccine development based on the progress made in SARS and MERS vaccine development | |
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| TWI605124B (zh) | 新穎桿狀病毒載體及使用方法 | |
| CN113666990B (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| Mitra-Kaushik et al. | Identification of a cytotoxic T-cell epitope on the recombinant nucleocapsid proteins of Rinderpest and Peste des petits ruminants viruses presented as assembled nucleocapsids | |
| JP2018536433A5 (OSRAM) | ||
| US12064477B2 (en) | HPV vaccine | |
| JP2017522907A5 (OSRAM) | ||
| JP2009540801A5 (OSRAM) | ||
| RU2017113571A (ru) | Рекомбинантные вакцины от fmdv и их применение | |
| HU229101B1 (en) | Dna transfection system for the generation of infectious influenza virus | |
| CN113930452B (zh) | 基于黑猩猩腺病毒载体的重组载体、腺病毒、2019新型冠状病毒疫苗及其制备方法 | |
| Small et al. | Viruses—From pathogens to vaccine carriers | |
| Smith et al. | The development of prophylactic and therapeutic EBV vaccines | |
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| CN113226364A (zh) | 组合物和方法 | |
| US20230372474A1 (en) | Recombinant hvt and uses thereof | |
| JP2019500320A5 (OSRAM) | ||
| Li et al. | A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice | |
| WO2015024484A1 (zh) | 一种新型狂犬病疫苗及其制备方法 |